Long-term, open-label (dose-blinded), extension study ofeptinezumab in children and adolescents with chronic or episodicmigraine

This project is a long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine. The study extends participation for pediatric subjects who have previously been exposed to eptinezumab in earlier trials, providing an opportunity to systematically document extended exposure to the investigational monoclonal antibody therapy in a younger population. As an extension study, its central purpose is to observe and characterize longer-term experience, including ongoing tolerability, safety signals, durability of clinical effects, and practical aspects of treatment administration under conditions that reflect continued therapeutic use beyond the initial controlled trial periods. The study's focus on both chronic and episodic migraine allows it to encompass the two major pediatric migraine presentations, enabling evaluation across a broad spectrum of disease burden and treatment response patterns among children and adolescents.

The open-label, dose-blinded design indicates that participants and caregivers are aware that active treatment is being administered while preserving blinding around the specific dose assignment; this permits collection of real-world adherence and tolerability data while maintaining methodological controls relevant to dose-response assessment. In the pediatric context, where growth, development, and longer-term safety considerations are paramount, such an extension study is structured to capture outcomes over an extended timeframe, including any emerging safety signals, effects related to repeated dosing, and the trajectory of migraine frequency and severity over time. The extension format also supports monitoring of participant retention, long-term acceptability of infusion or other administration procedures, and practical aspects of follow-up in pediatric cohorts.

By enrolling children and adolescents originally enrolled in preceding trials of eptinezumab, the extension aims to build a contiguous dataset that links acute and intermediate-term trial findings with long-term outcomes. This linkage is valuable for clinicians and families considering sustained preventive therapy in younger patients, for regulators assessing the risk benefit profile across longer exposure windows, and for investigators planning future pediatric research. The inclusion of both chronic and episodic migraine subgroups facilitates subgroup analyses that can inform whether long-term patterns differ by baseline migraine frequency and chronicity.